247 related articles for article (PubMed ID: 36915125)
1. Lipid metabolism-related miRNAs with potential diagnostic roles in prostate cancer.
Zhai T; Dou M; Ma Y; Wang H; Liu F; Zhang L; Chong T; Wang Z; Xue L
Lipids Health Dis; 2023 Mar; 22(1):39. PubMed ID: 36915125
[TBL] [Abstract][Full Text] [Related]
2. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
Ye Y; Li SL; Wang SY
PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
[TBL] [Abstract][Full Text] [Related]
3. Potential plasma microRNAs signature miR-190b-5p, miR-215-5p and miR-527 as non-invasive biomarkers for prostate cancer.
Khan MM; Serajuddin M; Bharadwaj M
Biomarkers; 2023 Mar; 28(2):227-237. PubMed ID: 36644827
[No Abstract] [Full Text] [Related]
4. Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract][Full Text] [Related]
5. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
6. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
7. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics.
Wang H; Yang L; Mi Y; Wang Y; Ma C; Zhao J; Liu P; Gao Y; Li P
Contrast Media Mol Imaging; 2022; 2022():6094409. PubMed ID: 35935308
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
Wu L; Quan W; Yue G; Luo Q; Peng D; Pan Y; Zhang G
BMC Cancer; 2021 Jan; 21(1):15. PubMed ID: 33402116
[TBL] [Abstract][Full Text] [Related]
10. Analysis of aberrant miRNA-mRNA interaction networks in prostate cancer to conjecture its molecular mechanisms.
Peng S; Liu C; Fan X; Zhu J; Zhang S; Zhou X; Wang T; Gao F; Zhu W
Cancer Biomark; 2022; 35(4):395-407. PubMed ID: 36373308
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
13. Construction of miRNA-mRNA-TF Regulatory Network for Diagnosis of Gastric Cancer.
Fu Z; Xu Y; Chen Y; Lv H; Chen G; Chen Y
Biomed Res Int; 2021; 2021():9121478. PubMed ID: 34840985
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
15. Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.
Feng F; Wu J; Gao Z; Yu S; Cui Y
Medicine (Baltimore); 2017 Jan; 96(1):e5679. PubMed ID: 28072703
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
17. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing.
Song C; Chen H; Wang T; Zhang W; Ru G; Lang J
Prostate; 2015 Apr; 75(5):500-16. PubMed ID: 25597612
[TBL] [Abstract][Full Text] [Related]
18. Construction of a transcription factor-miRNA-mRNA interactive network elucidates underlying pathogenesis for osteosarcoma and validation by qRT-PCR.
Tang F; Jiang X; Liao S; Liu Y; He M
Medicine (Baltimore); 2022 Oct; 101(41):e31049. PubMed ID: 36254052
[TBL] [Abstract][Full Text] [Related]
19. Signature microRNAs and long noncoding RNAs in laryngeal cancer recurrence identified using a competing endogenous RNA network.
Tang Z; Wei G; Zhang L; Xu Z
Mol Med Rep; 2019 Jun; 19(6):4806-4818. PubMed ID: 31059106
[TBL] [Abstract][Full Text] [Related]
20. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
